Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

• DOI: 10.1111/irv.13292
• Publication Date: 2024-04-24T05:00:13Z
• Authors: Susana Monge; James Humphreys; Nathalie Nicolay; Toon Braeye; Izaak Van Evercooren; Christian Holm Ha...; Hanne‐Dorthe Emborg; Chiara Sacco; Alberto Mateo‐Urd...; Jesús Castilla; Iván Martínez‐Baz; Brechje de Gier; Susan Hahné; Hinta Meijerink; Anja Bråthen Kris...; Ausenda Machado; Patricia Soares; Anthony Nardone; Sabrina Bacci; Esther Kissling; Baltazar Nunes
• Keywords: Booster dose; Dominance (genetics); Booster (rocketry)

ABSTRACT Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts used Cox models estimate adjusted hazard ratios derive VE. VE for was, respectively, 67% (95%CI: 58–74) 42–81) 65‐ 79‐year‐olds 66% 57–73) 72% 51–85) 80‐year‐olds. Results indicate that periodic vaccination of individuals 65 years has an ongoing benefit support current strategies EU/EEA.